Literature DB >> 16133550

Apolipoprotein E (APOE) and warfarin dosing in an Italian population.

Hugo Kohnke, Maria Gabriella Scordo, Vittorio Pengo, Roberto Padrini, Mia Wadelius.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16133550     DOI： 10.1007/s00228-005-0982-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  17 in total

Review 1.  The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis.

Authors:  K L Berkner; K W Runge
Journal:  J Thromb Haemost       Date:  2004-12       Impact factor: 5.824

2.  Studies on the optical enantiomorphs of warfarin in man.

Authors:  R A O'Reilly
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

3.  Warfarin dose related to apolipoprotein E (APOE) genotype.

Authors:  Hugo Kohnke; Kristina Sörlin; Göran Granath; Mia Wadelius
Journal:  Eur J Clin Pharmacol       Date:  2005-06-11       Impact factor: 2.953

Review 4.  Transport of vitamin K to bone in humans.

Authors:  M Kohlmeier; A Salomon; J Saupe; M J Shearer
Journal:  J Nutr       Date:  1996-04       Impact factor: 4.798

5.  Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations.

Authors:  G Eggertsen; R Tegelman; S Ericsson; B Angelin; L Berglund
Journal:  Clin Chem       Date:  1993-10       Impact factor: 8.327

Review 6.  Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.

Authors:  C S Landefeld; R J Beyth
Journal:  Am J Med       Date:  1993-09       Impact factor: 4.965

Review 7.  Causative and susceptibility genes for Alzheimer's disease: a review.

Authors:  A Rocchi; S Pellegrini; G Siciliano; L Murri
Journal:  Brain Res Bull       Date:  2003-06-30       Impact factor: 4.077

8.  The APOE gene and differences in life expectancy in Europe.

Authors:  Douglas C Ewbank
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2004-01       Impact factor: 6.053

9.  Variation of phylloquinone (vitamin K1) concentrations in hemodialysis patients.

Authors:  M Kohlmeier; J Saupe; H J Drossel; M J Shearer
Journal:  Thromb Haemost       Date:  1995-11       Impact factor: 5.249

10.  Mechanism of action of warfarin. Warfarin and metabolism of vitamin K 1 .

Authors:  R G Bell; J A Sadowski; J T Matschiner
Journal:  Biochemistry       Date:  1972-05-09       Impact factor: 3.162
View more
  13 in total

Review 1.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study.

Authors:  Vanessa Cristina de Oliveira Almeida; Daniel Dias Ribeiro; Karina Braga Gomes; Ana Lúcia Brunialti Godard
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

3.  Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.

Authors:  Mohamed Hossam A Shahin; Sherief I Khalifa; Yan Gong; Lamiaa N Hammad; Mohamed T H Sallam; Mostafa El Shafey; Shawky S Ali; Mohamed-Eslam F Mohamed; Taimour Langaee; Julie A Johnson
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

4.  Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients.

Authors:  Suman Lal; Edwin Sandanaraj; Srinivasa Rao Jada; Ming-Chai Kong; Lai-Heng Lee; Boon-Cher Goh; Soo-Chin Lee; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

Review 5.  Warfarin therapy: in need of improvement after all these years.

Authors:  Stephen E Kimmel
Journal:  Expert Opin Pharmacother       Date:  2008-04       Impact factor: 3.889

6.  Evaluation of genetic factors for warfarin dose prediction.

Authors:  Michael D Caldwell; Richard L Berg; Kai Qi Zhang; Ingrid Glurich; John R Schmelzer; Steven H Yale; Humberto J Vidaillet; James K Burmester
Journal:  Clin Med Res       Date:  2007-03

7.  The largest prospective warfarin-treated cohort supports genetic forecasting.

Authors:  Mia Wadelius; Leslie Y Chen; Jonatan D Lindh; Niclas Eriksson; Mohammed J R Ghori; Suzannah Bumpstead; Lennart Holm; Ralph McGinnis; Anders Rane; Panos Deloukas
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

Review 8.  Warfarin pharmacogenetics.

Authors:  Nita A Limdi; David L Veenstra
Journal:  Pharmacotherapy       Date:  2008-09       Impact factor: 4.705

9.  Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects?

Authors:  Liliya Alexandrovna Belozerceva; Elena Nikolaevna Voronina; Natalia Viktorovna Kokh; Galina Alexandrovna Tsvetovskay; Andrei Pavlovich Momot; Galina Israilevna Lifshits; Maxim Leonidovich Filipenko; Andrei Ivanovich Shevela; Valentin Viktorovich Vlasov
Journal:  EPMA J       Date:  2012-09-27       Impact factor: 6.543

10.  Failure to replicate a genetic association may provide important clues about genetic architecture.

Authors:  Casey S Greene; Nadia M Penrod; Scott M Williams; Jason H Moore
Journal:  PLoS One       Date:  2009-06-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.